Sapient Capital LLC Invests $667,000 in Astrazeneca Plc $AZN

Sapient Capital LLC acquired a new position in Astrazeneca Plc (NYSE:AZN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,800 shares of the company’s stock, valued at approximately $667,000.

A number of other institutional investors have also recently made changes to their positions in the business. Rossmore Private Capital lifted its position in Astrazeneca by 2.8% during the 4th quarter. Rossmore Private Capital now owns 66,392 shares of the company’s stock worth $11,652,000 after acquiring an additional 1,792 shares during the period. Abacus Wealth Partners LLC acquired a new stake in Astrazeneca during the 4th quarter worth about $2,218,000. Soltis Investment Advisors LLC lifted its position in Astrazeneca by 2.2% during the 4th quarter. Soltis Investment Advisors LLC now owns 3,470 shares of the company’s stock worth $609,000 after acquiring an additional 76 shares during the period. iA Global Asset Management Inc. lifted its position in Astrazeneca by 3.8% during the 4th quarter. iA Global Asset Management Inc. now owns 118,585 shares of the company’s stock worth $20,812,000 after acquiring an additional 4,396 shares during the period. Finally, May Hill Capital LLC lifted its position in Astrazeneca by 144.0% during the 4th quarter. May Hill Capital LLC now owns 23,974 shares of the company’s stock worth $4,207,000 after acquiring an additional 14,147 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on AZN shares. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 29th. Weiss Ratings started coverage on Astrazeneca in a research report on Wednesday, March 11th. They set a “buy (b)” rating for the company. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research report on Thursday, April 30th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, May 13th. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Astrazeneca presently has an average rating of “Moderate Buy” and an average target price of $205.33.

More Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Baxfendy (baxdrostat) won U.S. approval as the first aldosterone synthase inhibitor for adults with uncontrolled hypertension, giving AstraZeneca a first-in-class drug in a large market and raising expectations for meaningful future sales. Article: AstraZeneca’s blood pressure drug wins U.S. approval
• Positive Sentiment: Enhertu received FDA approval for two new HER2-positive early breast cancer settings, expanding the antibody-drug conjugate’s use and potentially boosting AstraZeneca’s oncology revenue through a broader patient population. Article: AZN, Daiichi’s Enhertu Gets FDA Nod for Two New Breast Cancer Settings
• Neutral Sentiment: Additional coverage highlighted AstraZeneca’s broader pipeline momentum, reinforcing investor interest in the company’s growth story, but without adding new material information beyond the FDA wins. Article: AstraZeneca wins US approval for first-in-class blood pressure drug and expands cancer treatment Enhertu

Astrazeneca Stock Performance

Shares of AZN stock opened at $183.97 on Tuesday. The stock has a market cap of $285.32 billion, a PE ratio of 27.62, a price-to-earnings-growth ratio of 1.49 and a beta of 0.26. The business has a 50-day simple moving average of $192.18 and a 200-day simple moving average of $182.29. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a 52-week low of $137.23 and a 52-week high of $212.71.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. On average, equities analysts expect that Astrazeneca Plc will post 10.26 EPS for the current year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.